Identification of four immune subtypes characterized by distinct composition and functions of tumor microenvironment in intrahepatic cholangiocarcinoma

Sylvie Job, Delphine Rapoud, Alexandre dos Santos, Patrick Gonzalez, Christophe Desterke, Gérard Pascal, Nabila Elarouci, Mira Ayadi, René Adam, Daniel Azoulay, et al.

To cite this version:
Sylvie Job, Delphine Rapoud, Alexandre dos Santos, Patrick Gonzalez, Christophe Desterke, et al.. Identification of four immune subtypes characterized by distinct composition and functions of tumor microenvironment in intrahepatic cholangiocarcinoma. Hepatology, 2019, 10.1002/hep.31092. pasteur-02611911

HAL Id: pasteur-02611911
https://pasteur.hal.science/pasteur-02611911
Submitted on 18 May 2020

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L’archive ouverte pluridisciplinaire HAL, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d’enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

Distributed under a Creative Commons Attribution - NonCommercial - ShareAlike 4.0 International License
Identification of four immune subtypes characterized by distinct composition and functions of tumor microenvironment in intrahepatic cholangiocarcinoma

**Short title:** Immune classification of ICC

Sylvie Job,1,7 Delphine Rapoud,2,3,7 Alexandre Dos Santos,2,3 Patrick Gonzalez,2,3 Christophe Desterke,3 Gérard Pascal,2,3 Nabila Elarouci,1 Mira Ayadi,1 René Adam,2,3 Daniel Azoulay,2,3 Denis Castaing,2,3 Eric Vibert,2,3 Daniel Cherqui,2,3 Didier Samuel,2,3 Antonio Sa Cuhna,2,3 Agnès Marchio4, Pascal Pineau4, Catherine Guettier,2,3,5 Aurélien de Reyniès,1 and Jamila Faivre2,3,6,*

1Ligue Nationale Contre le Cancer, Programme Cartes d’Identité des Tumeurs, F-75013 Paris, France

2INSERM, U1193, Paul-Brousse University Hospital, Hepatobiliary Centre, Villejuif 94800, France

3Univ. Paris-Sud, Université Paris-Saclay, Faculté de Médecine Le Kremlin-Bicêtre, France

4Institut Pasteur, Unité ‘Organisation Nucléaire et Oncogènes’, INSERM U993, Paris, France

This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the Version of Record. Please cite this article as doi: 10.1002/HEP.31092
Grant support: This work was supported by grants from the French National League Against Cancer (LNCC) under the Tumor Identity Cards (CIT) Program dedicated to cancer genomics. J.F. was supported by the Seventh Framework Programme (FP7) of the European Union under grant agreement No. 259743 (MODHEP consortium), the OSEO-BPI Programme d’Investissements d’Avenir (IMODI and HECAM consortiums; R14035LB and R15065LH, respectively).

Abbreviations used in this paper: CAF, cancer-associated fibroblasts; CCL, chemokine (C-C motif) ligand; CCR, CC chemokine receptor; CXCR, C-X-C chemokine receptor; EMT, epithelial-mesenchymal transition; EpCAM: epithelial cell adhesion molecule; FGFR, fibroblast growth factor receptor; KRT19: keratin 19; HCV, hepatitis C virus; HSC, hepatic stellate cells; ICC, intrahepatic cholangiocarcinoma; MCP-counter, Microenvironment cell population-counter; NK, natural killer; PD-1, programmed death 1; PD-L1, programmed death-ligand 1; TAMs, tumor-associated macrophages; TGF-β, transforming growth factor beta; WT, wild-type.

Correspondence

Address requests for reprints to: Prof. Jamila Faivre, MD, PhD, INSERM U1193, University Paris-Sud / Paris-Saclay, Paul-Brousse University Hospital, Hepatobiliary Centre, 14 Av. Paul Vaillant-Couturier, Villejuif 94800, France. email: jamila.faivre@inserm.fr; fax: (+33) 14 559 026

Conflicts of interest: The authors disclose no conflicts.

Transcript profiling: Accession number E-MTAB-6389

Author contributions
Sylvie Job and Delphine Rapoud share co-first authorship. Sylvie Job, Delphine Rapoud, Catherine Guettier, Aurélien de Reyniès and Jamila Faivre designed and implemented the study. Sylvie Job, Delphine Rapoud, Alexandre Dos Santos, Patrick Gonzalez, Christophe Desterke, Agnès Marchio, Pascal Pineau, Catherine Guettier and Jamila Faivre contributed to data acquisition. Nabila Elarouci and Mira Ayadi provided technical support. Gérard Pascal, René Adam, Daniel Azoulay, Denis Castaing, Eric Vibert, Daniel Cherqui, Didier Samuel, Antonio Sa Cuhna and Aurélien de Reyniès provided material support and significant insights. Sylvie Job and Christophe Desterke performed statistical and computational analysis. All the authors contributed to the analysis and interpretation of data, and the revision of the manuscript. Sylvie Job and Jamila Faivre drafted the manuscript. Jamila Faivre supervised the study.
Abstract

Background & Aims

Intrahepatic cholangiocarcinoma (ICC) is a severe malignant tumor in which the standard therapies are mostly ineffective. The biological significance of the desmoplastic tumor microenvironment (TME) of ICC has been stressed, but was insufficiently taken into account in the search for classifications of ICC adapted to clinical trial design. We investigated the heterogeneous tumor stroma composition and built a TME-based classification of ICC tumors, which detects potentially targetable ICC subtypes.

Methods

We established the bulk gene expression profiles of 78 ICCs. Epithelial and stromal compartments of 23 ICCs were laser microdissected. We quantified 14 gene-expression signatures of the TME and those of 3 functional indicators (liver activity, inflammation, immune resistance). The cell population abundances were quantified using the Microenvironment Cell Populations (MCP)-counter package and compared with immunohistochemistry. We performed an unsupervised TME-based classification of 198 ICCs (training set) and 368 ICCs (validation set). We determined immune response and signaling features of the different immune subtypes by functional annotations.

Results

We showed that a set of 198 ICCs could be classified into 4 TME-based subtypes related to distinct immune escape mechanisms and patient outcomes. The validity of these immune subtypes was confirmed over an independent set of 368 ICCs and by immunohistochemical analysis of 64 ICC tissue samples. About 45% of ICCs displayed an immune desert phenotype. The other subtypes differed in the nature (lymphoid, myeloid, mesenchymal) and abundance of tumor infiltrating cells. The inflamed subtype (11%) presented a massive T-lymphocyte infiltration, an activation of inflammatory and immune checkpoint pathways, and was associated with the longest patient survival.

Conclusion
We revealed the existence of an inflamed ICC subtype, which is potentially treatable with checkpoint blockade immunotherapy.

**Keywords:** Tumor microenvironment; Tumor heterogeneity; Tumor infiltrating leukocytes (TILs); Cancer Immunology; Immune Stratification.
**Introduction**

Cholangiocarcinoma is the second most common primary liver malignant tumor. It is classified as intrahepatic, perihilar and distal carcinomas according to the anatomical location of the tumor in the biliary tree. These types present clear differences in epidemiology, genetics, pathogenesis and prognosis, but each of them is highly heterogeneous from a genetic and phenotypic point of view, particularly intrahepatic cholangiocarcinoma (ICC). ICC, which is the most extensively studied type of cholangiocarcinoma, develops in small intrahepatic bile ducts and accounts for about 20% of primary hepatic cancers\(^1\). The diagnosis and staging of ICC are currently made by clinical examination, biochemical analysis and imaging of abdomen to delineate the biliary anatomy\(^2\). Usually, the disease already exhibits advanced non-specific symptoms with large tumors at the time of diagnosis. Local invasion, regional extension and distant metastases preclude resection in the majority of patients, and neither radiation nor standard-of-care chemotherapy regimen (gemcitabine and cisplatin) significantly improves survival\(^3\). Patients with unresectable ICC generally have a survival shorter than 12 months after diagnosis. Recurrence is common after liver resection and less than 40% of patients operated on survive more than 5 years.

ICC usually exhibits an abundant desmoplastic stroma containing a mixture of many non-immune and immune cell types, such as cancer-associated fibroblasts (CAFs) and tumor-associated macrophages (TAMs), which are negative prognostic factors\(^4,5\). It is known that a tumor reactive stroma provides an environment that favors tumor growth, metastasis, chemoresistance and tumor specific immune tolerance. A definition of ICC patient subgroups according to stromal signals and clinical features would permit a more effective disease management. Moreover, the therapeutic relevance of targeting stromal cell components to treat cancers is now well established. Immune checkpoint inhibitors, which can break tumor specific immune tolerance and thus allow tumor destruction, were used against advanced solid cancers with remarkable success in terms of rate of responder patients and long-lasting tumor responses in some patients and cancer types\(^6–8\). Immune checkpoint inhibitors also showed promising results in some patients with advanced hepatocellular carcinoma (HCC)\(^9\), but their possible effects against ICC have not yet been studied. Limited observations of high frequencies of tumor-infiltrating lymphocytes and PD-L1 expression in ICC patients suggest that a PD-1/PD-L1-based immunotherapy might benefit some ICC patients\(^10\).
Extensive molecular studies using omics-based bulk tumor tests led to the definition of ICC subtypes, which corresponded to specific genetic alterations and oncogenic pathways and correlated with patient outcome. These approaches were well suited to identifying drug-specific deregulated pathways, such as the ERBB2 (aka HER2) or fibroblast growth factor (FGF) signaling, but provided little information on the tumor microenvironment (TME). Such information could help to understand the mechanisms of disease progression and discover prognostic and treatment predictive biomarkers.

Characterizing TMEs and then classifying tumors according to TME composition requires particular technical and computational approaches. For this purpose, the usefulness of mass/flow cytometry or single-cell sequencing is limited by a number of factors, among which the large amounts of fresh tumors needed, the scarcity of phenotypic markers, and a long implementation time. Several computational methods have recently been developed to characterize the immune and non-immune stromal cell composition of bulk tumors from their whole transcriptomes.

All the available software tools, e.g. CIBERSORT and DeconRNA Seq, provide the relative proportions of different cell types within the TME, independently of the abundance of the TME relative to cancer load. The Microenvironment Cell Population (MCP)-counter, which relies on robust cell-type specific transcriptomic markers, provides, in addition, the actual amount (in arbitrary units) of each TME cell type within the sample, which allows the abundances of each cell type to be compared between samples.

During this study, we used the extensively validated MCP-counter tool to characterize the heterogeneous stromal landscape of ICCs from their bulk tumor transcriptomes in a cohort of 78 patients treated at the Paul-Brousse University Hospital and in 488 ICC samples from 6 publicly available transcriptomic datasets. We found that the ICC tumors could be categorized into four subtypes based on the cellular composition of the TME. These immune subtypes were corroborated by immunohistochemistry in the Paul-Brousse cohort and significantly correlated with patient outcomes in a cohort of 121 patients. The substantial differences in immune landscape, and thus immune evasion mechanisms, between the different ICC TME-based subtypes suggest that each ICC subtype should require a specific therapeutic strategy. Notably, we identified an immune-inflammatory subtype, which is potentially treatable with checkpoint blockade immunotherapy and represents about 10% of ICC patients.
Materials and Methods

Patient cohort

We surveyed 116 samples and files from patients with cholangiocarcinoma who underwent partial hepatectomy (n=108) or liver transplantation (n=8) at the Hepatobiliary Centre (HBC) of the Paul-Brousse University Hospital (Villejuif, France) upon approval of the institutional review board of the INSERM (IRB Number 11-047). The clinical and pathological records of the patients were carefully reviewed to eliminate perihilar, distal and combined hepato-cholangiocarcinoma. Finally, 78 ICC specimens were kept for implementation of the study. The tissue biobank of the Hospital Group of South of Paris (APHP) and the University of Paris-Sud (Paris 11) provided the liver specimens.

Sample selection, DNA methylation and RNA gene expression

Each frozen tumor block was cut at 5 μm and stained with hematein-eosin-saffron at two opposite ends and analyzed by an expert in liver pathology (CG) to evaluate the proportion of cancer cells, the degree of fibrosis/necrosis and the percent cellularity. 78 ICC samples were subjected to bulk-tumor RNA gene expression profiling, DNA-methylome analysis and immunohistochemistry for cancer-associated fibroblast and immune cell markers. Distant nontumor tissues were analyzed for 31 ICC samples. Epithelial and stromal compartments were microdissected by laser capture in 23 ICC samples. The transcriptome and methylome profilings were performed with the Affymetrix Human Transcriptome Array 2.0 (HTA 2.0) and Illumina HumanMethylation450 Array, respectively. Array data are available at ArrayExpress (accession number E-MTAB-6389).

Quantification of tumor-infiltrating immune cells

Tumor-infiltrating immune and non-immune cells were quantitatively determined from the bulk-tumor gene expression data using the MCP-counter package based on cell-type specific transcriptomic markers. To this aim, we used a set of 14 gene signatures comprising 11 signatures
from TME cell populations (activated fibroblasts, innate and adaptative immune cells) and 3 functional signatures (complement, inflammation, immune checkpoints). We also analyzed 6 public datasets (GSE26566, GSE32958, GSE89749, EGA00001000950, GSE33327, TCGA) including 488 ICC samples and 66 paired non-tumor liver samples.

**Statistical methods**

The analyses were performed using R software. A hierarchical clustering was applied to classify ICC tumors into unsupervised clusters using the expression data of the 14 TME-signatures. Consensus immune subtypes were obtained across datasets by hierarchical clustering of centroid correlations. Associations between immune subtypes, transcriptomic subtypes and clinicopathological covariates were analyzed with chi-square or Fisher-exact tests. The enrichment analyses of 20,929 signaling pathways were analyzed by hypergeometric tests. Overall survival curves were calculated by the Kaplan-Meier method and differences between curves were assessed using logrank tests. P-values <0.05 were deemed statistically significant.

Full details of the methods used are provided in the Supplementary Materials and Methods.
Results

Current transcriptome-based classifications fail to recognize tumor microenvironment diversity in ICC

Three different molecular classifications of ICCs into two prognostic subgroups based on whole-transcriptome analysis have been reported\textsuperscript{11–13}. The poor-prognosis subgroup was associated with stem cell-like (HpSC) features in the classification proposed by Oishi \textit{et al.}\textsuperscript{12} and with an activation of proliferative signaling (Cluster 2) in those proposed by Andersen \textit{et al.}\textsuperscript{11} and Sia \textit{et al.}\textsuperscript{13}. We performed bulk-tumor gene expression and histopathological analyses of 78 well-characterized ICC samples from patients who underwent partial hepatectomy or liver transplantation at the HBC between 2001 and 2014. Clinical and pathological characteristics of the cohort are summarized in Table 1. We assigned each ICC sample to the appropriate subtypes according to the three reported ICC classifiers and evaluated the correlation between the resulting classifications using Andersen \textit{et al.}'s one as a reference (Fig. 1A). Oishi \textit{et al.}'s classifier appeared to be highly (p<0.001), and Sia \textit{et al.}'s one moderately (p<0.05), concordant with Andersen \textit{et al.}'s one. This difference is perhaps due to the fact that Andersen \textit{et al.} and Oishi \textit{et al.} used frozen, and Sia \textit{et al.} FFPE, samples. We also classified our ICC samples using the Tumor Identity Card (CIT) unsupervised classifier developed by the French charity Ligue Nationale contre le Cancer. This yielded four transcriptomic classes named icc1 to icc4, which were found to be highly concordant with the reported classifications (Fig. 1A). We confirmed the presence of the four classes of the CIT classification in the GSE26566 (66 ICC and 59 paired non-tumor liver samples), GSE32958 (16 ICC, 7 paired non-tumor liver samples) and GSE32225 (149 ICC samples) public datasets (Supporting Fig.S1A). The icc4 subclass, which had the poorest overall survival in the Paul-Brousse cohort, corresponds to the published Cluster 2 and stem-cell-like poor-prognosis subclasses (Supporting Fig. S1B). Thus all the existing transcriptomic classifications seem to agree upon the existence of a poor-prognosis subclass, which roughly correspond to Andersen \textit{et al.}'s Cluster 2 subclass. The good-prognosis subclass (Cluster 1) seems to be less robust, being subdivided into several subsets, especially when the CIT classifier is used. We next carried out a thorough examination of the histopathological features (cancer cell aspect, abundance and cellularity of tumor stroma) of all 78 ICC tumors from the HBC. We found that the histological aspects of tumor tissues were spatially homogeneous in each sample but were highly variable (especially, as regards the stromal cell compartment) from sample to sample inside any
molecular subclass. No obvious systematic difference was observed between samples belonging to different subclasses (Fig. 1B). This highlights the fact that previously used methods yielded average signals from multicellular tissues and were insensitive to the phenotypic complexity of the ICC tumors. We therefore used the MCP-counter method, which yields distinct signals for distinct TME cells.

**A tumor microenvironment-based classification stratifies ICCs into four immune subtypes**

In order to build a TME-based classification of ICC tumors, we quantified several immune and non-immune cell populations in the ICC samples using MCP-counter, a computational method based on the use of specific cell-type transcriptomic signatures. We used a set of 14 gene signatures standing for the main infiltrated cell populations of the microenvironment of ICC tumors and some essential components of tumor-stroma interaction. We included the signatures of 8 TME cell populations labeled Fibroblasts, NK_or_T, Cytotoxic, B_derived, Myeloid, Lymphoid, T_adaptive and Monocyte Derived (MCP-counter package v0.1.26), respectively (Supporting Table S1). The Fibroblasts signature includes gene expression data of a diversity of primary and activated fibroblasts. Knowing the important role played by hepatic stellate cells (HSC) transdifferentiated into matrix producing myofibroblasts in liver fibrogenesis27,28, we added 3 signatures corresponding to quiescent, activated and fully transdifferentiated HSCs29. Finally, we added 3 functional signatures, namely, a signature of the complement system reflecting liver activity, a signature of genes involved in inflammatory pathways and cancer development30 and the signature of a set of immune checkpoint molecules known for their therapeutic interest31. We defined a training dataset (n=198) consisting of the CIT and GSE8974920 sets, and a validation dataset (n=368) composed of the GSE2656611, GSE3332713, EGA0000100095032, TCGA, GSE3295812 sets. The correlations between the different gene signatures in the training dataset revealed that the 11 TME cell population signatures aggregated in 3 distinct clusters corresponding to, firstly, activated fibroblasts (activated HSCs, fibroblasts, myofibroblasts), secondly, innate immune (monocyte-derived, myeloid) cells grouped with quiescent HSC and, thirdly, adaptive immune (NK_or_T, B-derived, cytotoxic, lymphoid) cells (Fig. 2A). The first (fibroblast) cluster showed a very low correlation with the other two clusters indicating an unrelated regulation of immune-cell activation and fibrogenesis. Hierarchical clustering using all
the 14 gene signatures showed various immune proto-subtypes of ICC with different immune patterns in the CIT and GSE89749 datasets (Fig. 2B), but only four immune subtypes emerged from the centroid-based correlation of the training dataset (Fig. 2C,D). These immune subtypes named I1 to I4, contained 48%, 9%, 13% and 28% of the ICCs, respectively. The same approach applied to the validation datasets yielded the same four immune subtypes containing 46%, 13%, 19% and 22% of the ICCs, respectively (Supporting Fig. S2). Subtype I1 displayed an immune desert pattern characterized by very weak expressions of all the molecular and functional TME signatures (Fig. 2D and Supporting Fig. S2C). Subtype I2 showed a reactive immunogenic pattern characterized by high amounts of recruited innate and adaptive immune cells, a strong activation of inflammatory and immune checkpoint pathways, and a significant amount of activated fibroblasts and quiescent HSCs. Subtype I3, called myeloid-rich for short, was characterized by a moderate to strong expression of monocyte-derived, myeloid and, to a lesser extent, fibroblast signatures, low expression of lymphoid signatures. Subtype I4 had mesenchymal features with a strong expression of the three signatures of activated fibroblasts. We tested the strength of the association between this new immune and the four existing whole-transcriptome classifications (Fig. 4A). We found that immune subtype I4 largely coclustered with the poor-prognosis (C2, HpSC-like, Proliferation, icc4) whole-transcriptome subtypes, while immune subtype I1 coclustered with the better-prognosis (C1, MH-like, Inflammation, icc2) ones. Immune subtypes I2 and I3 coclustered with both better-prognosis (C1) and poor-prognosis (HpSC-like, Proliferation and icc4) whole-transcriptome subtypes, highlighting the twofold (immune active and mesenchymal) nature of the TME in subtypes I2 and I3. (Fig. 4A). We quantified tumor cell infiltration in the different molecular subtypes using a score obtained by summing up the RNA expression levels of the specific gene markers of the 11 TME cell types (irrespective of their nature) tumor by tumor (Supporting Fig. S3). The immune subtypes ranked in ascending order of infiltration score are I1, I3, I4 and I2, in agreement with their TME gene profiles. Although, for a given classification system, the different whole-transcriptome subtypes could be split into strongly or weakly infiltrated tumors, they all contain tumors belonging to all four immune subtypes, confirming the better reliability of the immune subtype classification. This is further illustrated by the fact that most of the tumors belonging to Sia et al’s so-called ‘inflammation’ class were found to be immunologically silent (subtype I1), while those of the ‘proliferation’ class mostly belonged to non-I1 subtypes, in particular, immune active I2 or mesenchymal I4 subtypes (Fig. 4A).
The immune classification of ICCs is supported by immunophenotypic analysis

We performed immunostaining and quantified staining intensities in liver tumor sections from 64 of the 78 ICCs of known immune subtypes using several markers for immune and non-immune cells, namely, T-lymphocytes (CD4, CD8), memory T-cells (CD45RO), B-lymphocytes (CD20), macrophages (CD68), fibroblastic cells (alpha smooth muscle actin; αSMA) and mesenchymal cells (Vimentin). The distribution of the markers was remarkably reproducible from tumor to tumor in a given immune subtype and varied markedly from subtype to subtype (Fig. 3). αSMA and Vimentin are strongly expressed in the desmoplastic stroma in most immune subtypes, in agreement with previous reports (Supporting Fig. S4)\textsuperscript{33,34}. No significant difference in αSMA and Vimentin expressions was found between immune subtypes. In subtype I1, however, stromal fibroblasts express αSMA and Vimentin only weakly, or not at all, while tumor cells strongly express Vimentin. Overall stromal cellularity is low in subtype I1, high in subtype I4 and intermediate in subtypes I2 and I3 (Supporting Fig. S4). Subtype I2 displays a massive peri- and intratumor infiltration of CD4+, CD8+ and CD45RO+ lymphocytes (Fig. 3). B-lymphocyte clusters and scattered innate immune cells (macrophages) are also observed in the stroma of Subtype I2. By contrast, Subtype I1 shows no immune cells of any type inside the tumors, but only a weak occasional infiltration of T cells in the tumor margin. Subtype I3 contains a high density of macrophages, and a strong peritumor CD45RO+ T cell infiltration, which slightly penetrates into tumors. Subtype I4 has few immune cells inside the tumors and a low density of CD4+ T cells and macrophages in the tumor margin. Thus, the phenotypic features of the ICC tumors are in good agreement with the immune classification of ICCs based on gene expression profiles of tumor microenvironment cell populations. We also compared the present immune subtype classification with the histological classifications proposed by Nakanuma \textit{et al.}\textsuperscript{35} and Sigel \textit{et al.}\textsuperscript{36}. We found that no immune subtype displays a specific histological pattern. About 90% of our ICC samples belonged to Sigel \textit{et al.}’s SD (Small Duct) class in all the immune subtypes.

Functional characterization of the immune subtypes
To cast light on the stroma-cancer interaction in the different immune subtypes, we performed a functional enrichment analysis of the differentially expressed genes and a correlation study between molecular traits and clinical data in 520 ICCs (CIT, GSE26566, GSE33327, GSE89749 and EGA00001000950 datasets). In order to refine immune characterization, we used an additional set of functional immune signatures, including homemade signatures (Supporting Table S2) and CIBERSORT (Supporting Table S3). This revealed great differences in immune response and signaling between the different subtypes (Fig. 4A). I1 immune desert subtype displays a strong attenuation of tumor and stromal immune signaling, supporting its characterization as immune desert, most of the downregulated immune pathways being also hypermethylated (Figure 4A). I2 immunogenic subtype displays a strong lymphoid and myeloid immune response in an inflammatory microenvironment including an overexpression of major histocompatibility complex (MHC) class I and class II molecules, tertiary lymphoid structures, immune checkpoint molecules (among which CD86, CTLA4, PD-L1, PD-L2) as well as regulators of macrophage polarization and NF-κB pathway activation upon lipopolysaccharide (LPS) stimulation (Fig. 4A, D). The overexpression of immune checkpoints is associated with a hypomethylation of the corresponding genes in I2 compared to non-I2 subtypes, suggesting an epigenetic regulation of immune checkpoints (Fig. 4D). The most salient feature of I3 Myeloid subtype is a relatively strong expression of M2-polarized macrophage signature (Fig. 4A). Pathways and functional enrichment analyses showed that three important signalling pathways (T cell chemotaxis and activation; T cell survival; TLR3 type response) were differentially expressed according to immune subtype. I3 Myeloid subtype was significantly enriched for TLR3 type response and T cell chemotaxis/activation (the latter comprising the CD27-CD70 costimulatory pathway which promotes T cell priming and memory) but not for T cell survival (unlike I2 Immunogenic subtype, in which both T cell chemotaxis/activation and survival are activated). These observations may explain that, in I3 Myeloid subtype, infiltrating T cells are not capable of forming an efficient immune adaptive response against ICC. CIBERSORT analysis showed that 8 out of the 22 subsets of tumor-infiltrating immune cells used in this method were differentially represented in the different immune subtypes with an enrichment of M2 macrophages in I3 and CD8+ T cells in I2, supporting the myeloid and lymphoid nature of these subtypes, respectively (Supporting Table S3). I4 subtype, called Mesenchymal for short, displays a high abundance of activated HSC and an abundance of primary fibroblasts similar to that of I2 immunogenic subtype. It displays a set of enhanced tumorigenic factors involved in TGF-β and integrin signaling, extracellular matrix
(ECM) remodeling, EMT, and angiogenesis (Figure 4A). Moreover, it overexpresses a stem cell signature and several targets of KRAS and HNF1A compared to the other immune subtypes. We seeked correlations between the available clinico-biological features of the Paul-Brousse cohort and the different immune subtypes. The covariates that were found to be significant are displayed in Fig. 4B and C and those that were not significant in Supporting Table S4. We found no significant concentration of patients given neoadjuvant chemotherapy in a particular immune subtype. In other words, we did not detect any impact of neoadjuvant chemotherapy on ICC subtype. We also found that necrosis was evenly distributed among subtypes, and not preferentially accumulated in I3 Myeloid subtype. Globally, correlation studies revealed some significant clinico-pathological differences between the immune subtypes. I1 Immune desert subtype has a higher proportion of tumors with vascular emboli, lymphatic invasion and perineural invasion than the other subtypes. I2 Immunogenic subtype has an important proportion of alcohol drinking and cirrhotic patients, suggesting a link between the immune active response of this subtype and cirrhosis pathogenesis (immune dysfunction, systemic inflammation). I3 Myeloid subtype includes all the HCV-infected tumors, consistent with the mostly myeloid nature of this subtype and the ability of dying cells and HCV to trigger strong innate immune responses. Regarding prognosis markers, levels of Ca19.9 culminated in I4 Mesenchymal and those of EPCAM in I1 Immune desert subtypes. Knowing the possible impact of somatic alterations on immune response to cancer, we studied correlations between immune subtypes and gene mutations. We found no significant association between immune subtypes and IDH1, IDH2, KRAS, CTNNB1, PIK3CA or TP53 mutations (Fig. 4C), but found a positive correlation between the ICCs classified as ‘hypermutated’ by Nakamura et al. using whole-exome sequencing and I2 Immunogenic subtype (p=6e-04). We did not find any activation of the β-catenin signaling. We laser microdissected 23 ICCs, most (14) of which were I1 Immune desert samples. The stromal or epithelial nature of the different microdissected specimens was confirmed by transcriptomic analysis (Fig. 5A and Supporting Fig. S5). Laser microdissection data essentially confirmed the existence of a depleted immune TME in I1 compared to non-I1 subtypes, (p<1e-4) validating the MCP-counter method we used in bulk tumors. They also revealed, in microdissected tumor cells of I1 subtype, deregulated signaling pathways that had not been detected in bulk tumor transcriptomes (Fig. 5B). The TME depletion was associated with a hypermethylation of the corresponding genes, as was also observed in bulk ICC samples. The main upregulated pathways found in microdissected I1 tumor cells were pathways involved in xenobiotic metabolism, cell
growth and development through PPAR, FGFR and WNT signaling, respectively (p<1e-4) (Fig. 5C). We note that an activation of these signaling pathways in non-T cell-inflamed subtypes has been reported in several other solid cancers\textsuperscript{38,39}. We found an anticorrelation between gene expression level and methylation level for some deregulated pathways, in particular, immune and FGFR pathways, suggesting that they are epigenetically regulated (Fig. 5C).

The stromal and immune classification correlates with patient outcome

We investigated how patient outcome correlated with TME cell composition and immune subtype for the Paul-Brousse cohort (n=78) and for those patients of the GSE89749 dataset for whom survival data were available (n=45). Activated Fibroblasts signatures were found to be associated with poor prognosis by univariate analysis, consistent with the well-known detrimental role played by CAFs in cancer progression and metastasis\textsuperscript{4} (Fig. 6A and Supporting Fig. S6A). The bivariate analysis reveals a better prognosis associated with immune cells, which remained hidden by the detrimental effect of CAFs in the univariate analysis, highlighting the prognosis value of sets of (as opposed to individual) TME cell types and suggesting that some immune cells partly counteract the negative effect of CAFs (Fig. 6B and Supporting Fig. S6B). Significant differences in overall survival were found to exist between the different immune subtypes, suggesting that they might be clinically relevant subgroups (Fig. 6C and Supporting Fig. S6C). The 5 and 10-year average survivals of 78 patients of the Paul-Brousse cohort were of 38% and 12%, respectively. The median survival time was of 42 months for I1 Immune desert subtype, 73 months for I2 Immuneogenic subtype, 25 months for I3 Myeloid subtype and 19 months for I4 Mesenchymal subtype. The highest survival scores (60% at 5 years, 40% at 10 years) were those of I2 and the lowest (10% at 5 years, 0% at 10 years) those of I4 (Fig. 6C). A survival advantage of I1 and I2 with respect to I3 and I4 was also found in the pooled (Paul-Brousse and GSE89749) dataset (Supporting Fig. S6C). The survival plot according to immune subtype for the Paul-Brousse patients who were not given neoadjuvant chemotherapy (n=51) was not qualitatively different from that of the whole Paul-Brousse cohort, indicating that neoadjuvant chemotherapy did not have potentiator effects on any subtype (Fig. 6D). Univariate and multivariate Cox analyses showed that only the presence of satellite nodules was significantly associated with a poor overall survival (Supporting Tables S5 and S6).
**Discussion**

Tumor-stroma interaction is an essential component of cancer initiation, growth and progression, about which we had incomplete knowledge in the case of ICC. In this study, we provided a comprehensive molecular analysis of the tumor microenvironment of 566 ICCs using robust cell-type and functionality transcriptomic markers. We showed that the tumor microenvironments of ICCs display a large range of immunologic orientations and can be classified into four TME-based subtypes corresponding to different natures (lymphoid, myeloid, mesenchymal) and abundances of tumor infiltrating cells. This result was obtained using a consensus clustering approach that extracts robust (i.e. present in all the datasets we analyzed) core subtypes from the high TME complexity of ICC. Each core subtype is defined differentially, not by a single, but by a spectrum of immune signatures covering lymphoid, monocyte/myeloid and fibroblastic cells. A similar approach was previously used in colorectal and bladder cancers\textsuperscript{40,41}. Such an approach allows one to attenuate the impact of limitations inherent in genomic meta-analysis such as bias related to sample size and technology and provide a comprehensible view of the heterogeneous immune landscape of ICC. The proposed immune classification was confirmed by tissue immunostaining as regards cell types and abundances in the parenchyma and the stroma of the tumors, which incidentally provides a validation of MCP-counter as a reliable tool for quantifying the diverse cell populations of the TME from bulk tumor samples. These ICC immune subtypes bear similarities with previously reported cancer molecular subtypes\textsuperscript{42}. For instance, in colorectal cancer, an immune desert phenotype is associated with the consensus molecular subtype 3 (CMS3) and, interestingly, this poorly infiltrated subtype also exhibits an up-regulation of metabolic pathways, like ICC I1 Immune desert subtype\textsuperscript{40}. Colorectal CMS4 shares several features (mesenchymal phenotype, matrix remodeling, angiogenesis, poor overall survival) with ICC I4 Mesenchymal subtype. Colorectal microsatellite instable (MSI)-enriched CMS1 displays features of immunologically hot tumors (tumor infiltration, immune activation, elevated immune checkpoint expression), like ICC I2 Immunogenic subtype, suggesting that the latter have high MSI.

The different functional orientations of the ICC immune subtypes correspond to different immune escape mechanisms and, presumably, to different therapeutic options (Fig. 7). I1 Immune desert
subtype displays elements of immunologic ignorance (depletion in MHC class I, loss of β2-microglobulin) and a lack of T cells priming (absence of CD8-carrying T cells, lack of myeloid cells, non-inflamed tumor microenvironment), consistent with the current description of the cancer immune-desert phenotype (Figure 6A). However, the molecular mechanisms involved in this immunologically silent tumor phenotype are not known. I2 Immunogenic subtype has an inflammatory phenotype, which includes many types of immune cells (effector and memory T cells, B cells, macrophages) sitting close to tumor cells in an inflammatory tumor microenvironment enriched in both immunostimulating and immunosuppressive factors. This ambivalent immune profile suggests an effective antitumor immune response counteracted by negative immune regulators, such as immune checkpoints (CTLA4, CD274, PDCD1LG2) and TGF-β signaling. I3 Myeloid subtype tumors are infiltrated with M2 macrophages and CD4+ (and a few CD8+) T lymphocytes. The anti-inflammatory and immunosuppressive features of M2 macrophages could explain the lack of activated adaptive immunity observed in this subtype. I3 Myeloid subtype includes the few patients who presented with an HCV infection, which is known to trigger monocyte differentiation into polarized M2 macrophages. I4 Mesenchymal subtype displays high levels of vascular factors, chemokines and other paracrine factors produced by activated fibroblasts, which, presumably, enhance pro-tumorigenic pathways and restrain immune cell recruitment into the tumor tissue. It might correspond to the reported immune-excluded cancer category, in which an abundant fibrous stroma acts as a barrier preventing immune cells from accessing tumors.

From the therapeutic viewpoint, this study is an attempt to characterize ICC immune subtypes amenable to specific targeted therapies. It suggests that inflamed I2 Immunogenic subtype, which overexpresses immune checkpoints, is treatable with checkpoint blockade immunotherapy. It should be noted that the whole-transcriptome classifications of ICC fail to recognize the existence of such an immune active ICC subtype and assign the corresponding ICCs to either a good- or a poor-prognosis subclass in a classifier-dependent manner (Fig. 4A). Thus the TME-based classification of ICC might represent substantial progress in the identification of subtypes eligible for innovative therapies and precision cancer treatment (Figure 7B). Regarding non-inflamed I1 Immune desert subtype, the strategies against cold tumors currently under clinical evaluation consisting of converting them to inflamed tumors sensitive to cancer immunotherapy using various cytotoxic and modulating agents might be appropriate. The immunosuppressive TME of I3
Myeloid subtype might be targeted by drugs such as biphosphonate and the colony-stimulating factor 1 receptor (CSF1R) inhibitor, which induce depletion or reprogramming of M2 macrophages and thereby improve host’s antitumor immune response and sensitivity to cancer immunotherapy. The fibrotic barrier observed in I4 Mesenchymal subtype might be altered by anti-fibrotic therapy allowing immune cells to access tumor cells.

In conclusion, this study is the first to mine transcriptomes in order to characterize finely the heterogeneity of ICC tumor microenvironment. It identifies four different TME-based subtypes with distinct mechanisms of immune dysfunction associated with different patient outcomes. This immune classification might serve as a basis for the design of clinical trials aiming to test biology-guided immunotherapy options in ICC.

Acknowledgements

We are grateful to Dr. M.A. Buendia and Dr. F. Ghiringelli for fruitful discussions. We also thank N. Lablack (laser microdissection), O. Trassard (slide scanning) and the IGBMC Platform (microarray) for assistance with this study. We thank the Tissue Biobank Group of the AP-HP (CRB Paris-Sud) for providing human tissue specimens.
**LEGENDS**

**Figure 1:** The existing molecular subtypes of ICC display highly variable tumor microenvironment patterns. (A) Visualization of the contingency tables of four ICC classifiers (S1-S4) applied to the 78 ICC transcriptomes of this study. S1: Andersen et al’s classification\(^{11}\). S2: Oishi et al’s classification\(^{12}\). S3: Sia et al’s classification\(^{13}\). S4: this study. S1 was used as reference. The order of ICC tumors along the horizontal axis is the same for all the classifications. ST: subtypes. *P<0.05, ***P <0.001. P: Chi-square-test P value. (B) Histological analysis of tumors assigned to the C1 and C2 molecular subtypes of Andersen et al’s classification. Representative tumor cells (top) and tumor microenvironments (bottom) for a given ICC patient. Scale bar: 50µm.

**Figure 2:** A tumor microenvironment-based classification stratifies ICCs into four immune subtypes. (A) Correlation matrices of 11 signatures of immune and stromal cell populations in two datasets. Dataset1 (CIT): this study; Dataset2 (Jusakul et al.): GSE89749\(^{20}\). Color scale: Pearson correlation coefficient from 0 (blue) to 1 (red). (B) Hierarchical clustering of the ICCs of the two datasets using expression levels of 14 stromal and immune signatures. The number of TME-based clusters for each dataset was determined by the silhouette metric. Color scale: expression level from -2 (blue) to +2 (red). (C) Centroid correlation of the clusters identified in (B) highlighting the existence of four TME-based subtypes. Color scale: Pearson correlation coefficient from 0 (blue) to 1 (red). (D) Heatmap of the centroids of the four TME-based subtypes labeled from I1 to I4. Color scale: expression level from low (blue) to high (red).

**Figure 3:** Tissue immunostaining supports the existence of distinct ICC immune subtypes. (A) Representative immunohistochemical images of formalin-fixed paraffin-embedded ICC samples belonging to the indicated TME-based subtypes and stained with the indicated specific
antibodies. Visualization of different areas of the same tumor sample belonging to the indicated subtypes. Scale bar: 100µm. (B) Quantification of staining intensities for the indicated immune markers performed in 64 ICC samples grouped into immune subtypes labeled from I1 to I4. *P<0.05, **P<0.01 (Anova test).

**Figure 4: Functional orientation of the different ICC immune subtypes.** (A-C) Clinico-molecular covariates attributed to the different immune subtypes with their phenotypic denominations. (A) Top: Proportion of samples belonging to the reported ICC molecular classification. Bottom: Heatmap of the mean expression levels of gene sets involved in the indicated pathways and MSigDB signatures. Color scale: from low (blue) to high (red). P values: hypergeometric test. Pins: deregulated methylated pathways. (B) Proportion of samples harboring the indicated clinical covariate in a given immune subtype. VELIPI; vascular emboli, lymphatic invasion and perineural invasion histological criteria. Ca19-9 value: serum concentration of the tumor marker carbohydrate antigen 19-9. Neoadj.: neoadjuvant. Color scale: expression level from -2 (blue) to +2 (red). (C) Proportion of samples harboring the indicated mutated genes. (D) Mean expression levels of a set of immune checkpoint molecules in the I2 compared to the non-I2 subtypes in all six ICC datasets. Color scale: expression level (Exp) from -2 (blue) to +2 (red). DNA methylation levels of the immune checkpoints in the dataset from this study (CIT). Color scale: beta value (Methy) from -0.2 (blue) to +0.2 (yellow).

**Figure 5: Functional features of laser microdissected stromal and tumor cells of immunologically silent ICCs.** (A) Mean expression levels of genes involved in cell cycle regulation or extracellular matrix remodeling in I1 ICC samples enriched in stromal or cancer cells. (B) Mean expression levels of the immune response genes most differentially expressed in I1 and non-I1 ICCs in microdissected stromal cells. (C) Sketch of the genes and pathways most differentially expressed in I1 and non-I1 microdissected cancer cells. Grey stripe: plasma
membrane. (A-C) P values: hypergeometric test. Color scale: expression level (Exp) from -2 (blue) to +2 (red). Pins: deregulated methylated pathways.

**Figure 6: Correlation between ICC immune subtype and patient overall survival.** Relationship between immune and stromal signatures and patient overall survival in the Paul-Brousse patient cohort as revealed by Cox analysis. H.R.: Hazard Ratio. Blue squares: P≥0.05. Orange squares: P<0.05. (A) Univariate Cox analysis. P: logrank-test P values. (B) Bivariate Cox analysis. P: Wald-test P values. Grey squares: fibroblast hazard ratios. Orange squares: hazard ratios of the indicated stromal and immune signatures (P<0.05). (C,D) Kaplan-Meier curves of overall patient survival for the indicated ICC immune subtypes. P: logrank-test P value. (C) Whole cohort: Paul-Brousse cohort (n=78). (D) Paul-Brousse patients who were not given neoadjuvant chemotherapy (n=51).

**Figure 7: Outline of (A) the mechanisms to evade tumor immune elimination and (B) the possible therapeutic strategies for the different ICC immune subtypes.**

**Table 1:** Clinical and pathological features of the Paul-Brousse patient cohort. IQR: interquartile range.
References

1. Poultsides, G. A., Zhu, A. X., Choti, M. A. & Pawlik, T. M. Intrahepatic cholangiocarcinoma. *Surg. Clin. North Am.* 90, 817–837 (2010).
2. Rizvi, S., Khan, S. A., Hallemeier, C. L., Kelley, R. K. & Gores, G. J. Cholangiocarcinoma - evolving concepts and therapeutic strategies. *Nat. Rev. Clin. Oncol.* 15, 95–111 (2018).
3. Valle, J. *et al.* Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. *N. Engl. J. Med.* 362, 1273–1281 (2010).
4. Sirica, A. E. The role of cancer-associated myofibroblasts in intrahepatic cholangiocarcinoma. *Nat. Rev. Gastroenterol. Hepatol.* 9, 44–54 (2011).
5. Sirica, A. E. & Gores, G. J. Desmoplastic stroma and cholangiocarcinoma: clinical implications and therapeutic targeting. *Hepatol. Baltim. Md* 59, 2397–2402 (2014).
6. Wolchok, J. D., Rollin, L. & Larkin, J. Nivolumab and Ipilimumab in Advanced Melanoma. *N. Engl. J. Med.* 377, 2503–2504 (2017).
7. Brahmer, J. *et al.* Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. *N. Engl. J. Med.* 373, 123–135 (2015).
8. Robert, C. *et al.* Pembrolizumab versus Ipilimumab in Advanced Melanoma. *N. Engl. J. Med.* 372, 2521–2532 (2015).
9. El-Khoueiry, A. B., Sangro B *et al.* Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial. *Lancet Lond. Engl.* 389, 2492–2502 (2017).
10. Sabbatino, F. *et al.* PD-L1 and HLA Class I Antigen Expression and Clinical Course of the Disease in Intrahepatic Cholangiocarcinoma. *Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res.* 22, 470–478 (2016).
11. Andersen, J. B. *et al.* Genomic and genetic characterization of cholangiocarcinoma identifies therapeutic targets for tyrosine kinase inhibitors. *Gastroenterology* 142, 1021-1031.e15 (2012).
12. Oishi, N. *et al.* Transcriptomic profiling reveals hepatic stem-like gene signatures and interplay of miR-200c and epithelial-mesenchymal transition in intrahepatic cholangiocarcinoma. *Hepatol. Baltim. Md* 56, 1792–1803 (2012).
13. Sia, D. *et al.* Integrative molecular analysis of intrahepatic cholangiocarcinoma reveals 2 classes that have different outcomes. *Gastroenterology* 144, 829–840 (2013).
14. Chan-On, W., Nairismägi M-L, Ong CK, Lim WK, et al. Exome sequencing identifies distinct mutational patterns in liver fluke-related and non-infection-related bile duct cancers. Nat. Genet. 45, 1474–1478 (2013).

15. Gao, Q., Zhao Y-J, Wang X-Y, et al. Activating mutations in PTPN3 promote cholangiocarcinoma cell proliferation and migration and are associated with tumor recurrence in patients. Gastroenterology 146, 1397–1407 (2014).

16. Borad, M. J., Champion MD, Egan JB, et al. Integrated genomic characterization reveals novel, therapeutically relevant drug targets in FGFR and EGFR pathways in sporadic intrahepatic cholangiocarcinoma. PLoS Genet. 10, e1004135 (2014).

17. Zou, S. et al. Mutational landscape of intrahepatic cholangiocarcinoma. Nat. Commun. 5, 5696 (2014).

18. Razumilava, N. & Gores, G. J. Cholangiocarcinoma. Lancet Lond. Engl. 383, 2168–2179 (2014).

19. Farshidfar, F. et al. Integrative Genomic Analysis of Cholangiocarcinoma Identifies Distinct IDH-Mutant Molecular Profiles. Cell Rep. 19, 2878–2880 (2017).

20. Jusakul, A. et al. Whole-Genome and Epigenomic Landscapes of Etiologically Distinct Subtypes of Cholangiocarcinoma. Cancer Discov. 7, 1116–1135 (2017).

21. Arai, Y. et al. Fibroblast growth factor receptor 2 tyrosine kinase fusions define a unique molecular subtype of cholangiocarcinoma. Hepatol. Baltim. Md 59, 1427–1434 (2014).

22. Chevrier, S. et al. An Immune Atlas of Clear Cell Renal Cell Carcinoma. Cell 169, 736–749.e18 (2017).

23. Tirosh, I., Izar B, et al. Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq. Science 352, 189–196 (2016).

24. Newman, A. M., Liu CL, et al. Robust enumeration of cell subsets from tissue expression profiles. Nat. Methods 12, 453–457 (2015).

25. Gong, T. & Szustakowski, J. D. DeconRNASeq: a statistical framework for deconvolution of heterogeneous tissue samples based on mRNA-Seq data. Bioinforma. Oxf. Engl. 29, 1083–1085 (2013).

26. Becht, E. et al. Estimating the population abundance of tissue-infiltrating immune and stromal cell populations using gene expression. Genome Biol. 17, (2016).

27. Friedman, S. L. Hepatic stellate cells: protean, multifunctional, and enigmatic cells of the liver. Physiol. Rev. 88, 125–172 (2008).
28. Kang, N., Gores, G. J. & Shah, V. H. Hepatic stellate cells: partners in crime for liver metastases? Hepatol. Baltim. Md 54, 707–713 (2011).
29. Boers, W. et al. Transcriptional profiling reveals novel markers of liver fibrogenesis: gremlin and insulin-like growth factor-binding proteins. J. Biol. Chem. 281, 16289–16295 (2006).
30. Darnaud, M., Dos Santos A, Gonzalez P, et al. Enteric Delivery of Regenerating Family Member 3 alpha Alters the Intestinal Microbiota and Controls Inflammation in Mice With Colitis. Gastroenterology 154, 1009-1023.e14 (2018).
31. Taube, J. M. et al. Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy. Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res. 20, 5064–5074 (2014).
32. Nakamura, H. et al. Genomic spectra of biliary tract cancer. Nat. Genet. 47, 1003–1010 (2015).
33. Dos Santos, A. et al. Identification of cellular targets in human intrahepatic cholangiocarcinoma using laser microdissection and accurate mass and time tag proteomics. Mol. Cell. Proteomics MCP 9, 1991–2004 (2010).
34. Vaquero, J. et al. Epithelial-mesenchymal transition in cholangiocarcinoma: From clinical evidence to regulatory networks. J. Hepatol. 66, 424–441 (2017).
35. Nakanuma, Y. & Kakuda, Y. Pathologic classification of cholangiocarcinoma: New concepts. Best Pract Res Clin Gastroenterol. 29, 277-93 (2015).
36. Sigel, C.S. et al. Intrahepatic Cholangiocarcinomas Have Histologically and Immunophenotypically Distinct Small and Large Duct Patterns. Am J Surg Pathol. 42, 1334-1345 (2018).
37. Albillos, A., Lario, M. & Álvarez-Mon, M. Cirrhosis-associated immune dysfunction: distinctive features and clinical relevance. J. Hepatol. 61, 1385–1396 (2014).
38. Sweis, R. F. et al. Molecular Drivers of the Non-T-cell-Inflamed Tumor Microenvironment in Urothelial Bladder Cancer. Cancer Immunol. Res. 4, 563–568 (2016).
39. Luke, J. J., Bao, R., Sweis, R. F., Spranger, S. & Gajewski, T. F. WNT/β-catenin Pathway Activation Correlates with Immune Exclusion across Human Cancers. Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res. 25, 3074–3083 (2019).
40. Guinney, J., Dienstmann R, Wang X, de Reyniès A, Schlicker A, Soneson C, et al. The consensus molecular subtypes of colorectal cancer. Nat. Med. 21, 1350–1356 (2015).
41. Kamoun, A. et al. A Consensus Molecular Classification of Muscle-invasive Bladder Cancer. *Eur. Urol.* (2019) doi:10.1016/j.eururo.2019.09.006.

42. Becht, E. et al. Immune and Stromal Classification of Colorectal Cancer Is Associated with Molecular Subtypes and Relevant for Precision Immunotherapy. *Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res.* (2016) doi:10.1158/1078-0432.CCR-15-2879.

43. Saha, B., Kodys, K. & Szabo, G. Hepatitis C Virus-Induced Monocyte Differentiation Into Polarized M2 Macrophages Promotes Stellate Cell Activation via TGF-β. *Cell. Mol. Gastroenterol. Hepatol.* 2, 302-316.e8 (2016).

44. Chen, D. S. & Mellman, I. Elements of cancer immunity and the cancer-immune set point. *Nature* 541, 321–330 (2017).

45. Galon, J. & Bruni, D. Approaches to treat immune hot, altered and cold tumours with combination immunotherapies. *Nat. Rev. Drug Discov.* (2019) doi:10.1038/s41573-018-0007-y.

46. Zhu, Y. et al. CSF1/CSF1R blockade reprograms tumor-infiltrating macrophages and improves response to T-cell checkpoint immunotherapy in pancreatic cancer models. *Cancer Res.* 74, 5057–5069 (2014).
| Variables                                      | n=78     |
|------------------------------------------------|---------|
| Gender, male (%)                               | 38 (48.7)|
| Median age (IQR)                               | 62 (52-69)|
| Obesity, BMI>=30                               | 13 (17.1)|
| Risk Factor (%)                                |         |
| Primary sclerosing cholangitis                 | 6 (7.7)  |
| Alcohol abuse                                  | 9 (13)   |
| Hemochromatosis                                | 2 (2.8)  |
| Diabetes                                       | 7 (9.1)  |
| Metabolic syndrome                             | 2 (2.5)  |
| Hepatitis C                                    | 2 (3.1)  |
| Hepatitis B                                    | 3 (4.6)  |
| Underlying liver (%)                           |         |
| Healthy                                        | 20 (27)  |
| Cirrhosis                                      | 12 (5.4) |
| Fibrosis                                       | 28 (16.2)|
| Steatosis                                      | 38 (27)  |
| Cholestasis                                    | 5 (4.1)  |
| Tumor differentiation (%)                      |         |
| Well                                           | 22 (29.7)|
| Moderate                                       | 37 (50)  |
| Poor                                           | 15 (20.3)|
| Multiple nodules (%)                           |         |
| Absent                                         | 46 (59)  |
| Present                                        | 32 (41)  |
| Tumor size, cm (%)                             |         |
| <5                                             | 16 (20.5)|
| >5 and <10                                     | 40 (51.3)|
| >10                                            | 22 (28.2)|
| Vascular invasion (%)                          |         |
| Absent                                         | 27 (34.6)|
| Present                                        | 51 (65.4)|
| Perineural invasion                            |         |
| Absent                                         | 56 (71.8)|
| Present                                        | 22 (28.2)|
| Necrosis (%)                                   |         |
| Absent                                         | 50 (65.8)|
| Present                                        | 26 (34.2)|
| IDH1 mutation (%)                              |         |
| Absent                                         | 70 (89.8)|
| Present                                        | 8 (10.2) |
| IDH2 mutation (%)                              |         |
| Absent                                         | 74 (94.9)|
| Present                                        | 4 (5.1)  |
| Median Ca19-9 value (U/mL)                     | 73 (18-527)|
| Preoperative chemotherapy (%)                  |         |
| Absent                                         | 53 (67.9)|
| Present                                        | 25 (32.1)|
| Events                                         |         |
| Recurrence                                     | 54 (69.2)|
| Death                                          | 51 (67.1)|
ICC classifiers:
Andersen et al. ST
Oishi et al. ST
Sia et al. ST
CIT ST

C1
MH.like
HpSC.like
Inflammation
Proliferation

Patient 52
Patient 53
Patient 59
Patient 5

---

hep_31092_f1.eps
Dataset 1 (CIT) Dataset 2 (Jusakul et al.)

Tumor samples (N=78) Tumor samples (N=120)

Centroid correlation

Fibroblast HSCactivated Myofibroblast Myeloid B Derived Cytotoxic Lymphoid NK_or_T T_adaptive

Activated fibroblasts Innate immunity Adaptive immunity

Complement proinflammation checkpoint

Fibroblast HSCactivated Myofibroblast B Derived Cytotoxic Lymphoid NK_or_T T_adaptive

Complement proinflammation checkpoint

NT
cor
1
0.8
0.6
0.4
0.2
0
cor
1
0.8
0.6
0.4
0.2
0

Exp
2
10
-1
-2
Exp
2
10
-1
-2
A

CD4

CD8

CD20

CD45RO

CD68

I1 (n=38)  I2  (n=7)  I3 (n=8)  I4 (n=11)

B

Marker intensity score

Very weak  Weak  Moderate  Strong

Numbers of ICC (percentage)
**A**

| Cell Type              | Hazard Ratio (95% C.I.) | p       |
|------------------------|-------------------------|---------|
| Myofibroblast          | 3.16 (1.50-6.60)        | 0.0021  |
| HSC activated          | 3.10 (1.40-7.00)        | 0.0056  |
| Fibroblast             | 2.05 (1.10-3.70)        | 0.017   |
| Lymphoid               | 1.48 (0.70-3.10)        | 0.31    |
| Cytotoxic              | 0.78 (0.46-1.30)        | 0.36    |
| Complement             | 1.23 (0.76-2.00)        | 0.39    |
| Proinflammatory        | 1.14 (0.76-1.70)        | 0.53    |
| Monocyte derived       | 0.89 (0.58-1.40)        | 0.61    |
| Myeloid                | 1.13 (0.60-2.10)        | 0.7     |
| NK_or_T                | 0.93 (0.60-1.40)        | 0.73    |
| HSC quiescent          | 1.11 (0.59-2.10)        | 0.75    |
| B derived              | 0.93 (0.49-1.80)        | 0.82    |
| T adaptive             | 0.98 (0.54-1.70)        | 0.93    |
| Checkpoint             | 1.00 (0.50-2.00)        | 1       |

**B**

| Cell Type              | Hazard Ratio (95% C.I.) | p       |
|------------------------|-------------------------|---------|
| NK_or_T                | 0.46 (0.24-0.90)        | 0.022   |
| T adaptive             | 0.34 (0.12-0.96)        | 0.041   |
| Cytotoxic              | 0.42 (0.20-0.86)        | 0.018   |
| Monocyte derived       | 0.57 (0.35-0.95)        | 0.03    |
| HSC quiescent          | 0.35 (0.14-0.90)        | 0.29    |

**C**

- **Whole cohort**
  - Hazard Ratio: 3.16 (95% C.I.: 1.50-6.60), p = 0.0021

**D**

- **Patients w/o neoadjuvant chemotherapy**
  - Hazard Ratio: 0.46 (95% C.I.: 0.24-0.90), p = 0.022
